This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Innate Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.645. Innate Pharma's 10-Year median PS Ratio is 8.8992. Therefore, the Median PS Value for today is €5.74.
As of today (2024-05-23), Innate Pharma's share price is €2.425. Innate Pharma's Median PS Value is €5.74. Therefore, Innate Pharma's Price to Median PS Value for today is 0.42.
The historical rank and industry rank for Innate Pharma's Median PS Value or its related term are showing as below:
LTS:0EVI'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.4 Med: 0.53 Max: 3.03
Current: 0.42
During the past 13 years, the highest Price to Median PS Value of Innate Pharma was 3.03. The lowest was 0.40. And the median was 0.53.
LTS:0EVI's Price-to-Median-PS-Value is ranked better than 72.41% of 261
companies
in the Biotechnology industry
Industry Median: 0.68
vs LTS:0EVI: 0.42
Innate Pharma Median PS Value Historical Data
The historical data trend for Innate Pharma's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Innate Pharma's Median PS Value
For the Biotechnology subindustry, Innate Pharma's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innate Pharma's Price-to-Median-PS-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innate Pharma's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Innate Pharma's Price-to-Median-PS-Value falls into.
Innate Pharma Median PS Value Calculation
Innate Pharma's Median PS Value for today is calculated as
10-Year Median PS Ratio is 8.8992.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Innate Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.645.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innate Pharma (LTS:0EVI) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Innate Pharma's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
2.425
/
5.74
=
0.42
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innate Pharma Median PS Value Related Terms
Thank you for viewing the detailed overview of Innate Pharma's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0EVI has been successfully added to your 